Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

International Trial of the Edmonton protocol for Islet Transplantation

Academic Article
Publication Date:
2006
abstract:
Background
This international multicenter trial explores the feasibility and reproducibility of islet transplantation using a single common protocol (Edmonton Protocol ) for islet manufacture and post-transplant management.
Methods
A total of 36 subjects underwent islet transplantation at 9 international sites (6 in North America, 3 in Europe). Islets were prepared from cadaveric donors, purified, and transplanted within two hours, without culture. The primary endpoint was defined as the proportion of subjects that remained insulin independent with adequate glycemic control at one year following their final transplant.
Results
16/36 (44%, CI 30% - 61%) subjects achieved the primary endpoint, 10 (28%) demonstrated partial islet function, and 10 had complete graft loss before one year. 22/36 (61%) derived benefit at one year post final transplant as demonstrated by insulin independence or reduced insulin requirement, HbA1C <6.5%, stimulated C-peptide >0.3ng/mL and protection from severe hypoglycemia. Of 21/36 (58%) subjects attaining primary endpoint criteria at any point throughout the trial, 15/21 (71%) became dependent on insulin again by two years.
Conclusions
This multicenter trial confirms that islet transplantation successfully restores long-term endogenous insulin production and glycemic stability in T1DM subjects with unstable baseline control, but insulin independence is usually evanescent over time. Persistent islet function despite loss of insulin independence provided complete protection from severe hypoglycemia and improved HbA1C. Islet transplantation is an appropriate therapy for highly selected subjects with severe hypoglycemia or labile diabetes, provided all other attempts to stabilize glycemic control have been exhausted.
Iris type:
1.1 Articolo in rivista
List of contributors:
A. M., JAMES SHAPIRO; M. D, P. H. D; Camillo, Ricordi; M., D.; BERNHARD J., Hering; M., D.; Hugh, Auchincloss; M., D.; Robert, Lindblad; M., D.; R., PAUL ROBERTSON; M., D.; Secchi, Antonio; M., D.; MATHIAS D., Brendel; M., D.; Thierry, Berney; M., D.; DANIEL C., Brennan; M., D.; Enrico, Cagliero; M., D.; Rodolfo, Alejandro; M., D.; EDMOND A., Ryan; M., D.; Barbara, Dimercurio; R., N.; Philippe, Morel; M., D.; KENNETH S., Polonsky; M., D.; JO ANNA, Reems; P. H., D.; REINHARD G., Bretzel; M., D.; Federico, Bertuzzi; M., D.; Tatiana, Froud; M., D.; Raja, Kandaswamy; M., D.; DAVID E. R., Sutherland; M. D, P. H. D; George, Eisenbarth; M. D, P. H. D; Miriam, Segal; P. H., D.; Jutta, Preiksaitis; M., D.; GREGORY S., Korbutt; P. H., D.; FRANCA B., Barton; M., S.; Lisa, Viviano; R., N.; VICKI SEYFERT, Margolis; P. H., D.; Jeffrey, Bluestone; P. H., D.; AND JONATHAN R. T., Lakey; P. H., D.
Handle:
https://iris.unisr.it/handle/20.500.11768/14905
Published in:
THE NEW ENGLAND JOURNAL OF MEDICINE
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.7.2.0